Neurology Central

Sumatriptan iontophoretic transdermal system for the acute treatment of migraine


We will describe the pharmacokinetic profile, clinical efficacy and safety data of the sumatriptan iontophoretic transdermal system (Zecuity®, NuPathe Inc., PA, USA), recently approved for the acute treatment of migraine with or without aura in adults, by the US FDA. This transdermal system utilizes a low-level electrical current to deliver sumatriptan transdermally and circumvents the GI tract.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.